Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies Authors: Myriam Reisch, Jens Thiel, Philipp Bosch Published: 2026 ABSTRACT AbstractLarge vessel vasculitides (LVV), including giant cell arteritis (GCA) and Takayasu arteritis (TAK), share common features such as inflammation of large sized arteries but differ in several key aspects, including age of onset and pathogenic mechanism. This narrative review gives an update of recent insights into pathogenesis of GCA and TAK, and discusses emerging targeted therapies based on these insights. It highlights omics-based signatures, ULK3 and SLAMF7 in GCA, EGR1 in TAK, alongside genetic and somatic risk factors such as clonal haematopoiesis (DNMT3A/TET2) linked to relapse and ischaemic vision loss in GCA, and the IL6R-p.Asp358Ala variant as a predictor of reduced interleukin (IL)-6 receptor blockade response. Common mechanisms include CD4⁺ T-cell, monocyte/macrophage, and B-cell infiltration with activation of IL-6, JAK/STAT/interferon, and IL-17 pathways. Giant cell arteritis is characterised by GM-CSF-driven macrophages and disrupted programmed cell death (PD)-1/PD-L1 checkpoint regulation, while TAK shows dominance of CD8⁺ T cells and tumour necrosis factor (TNF)-α signalling. Interleukin-6 receptor inhibitors (e.g., tocilizumab) show robust efficacy in GCA but with notable non-responders; the JAK inhibitor upadacitinib demonstrated efficacy in a Phase III study, whereas IL-17 blockade (secukinumab) yielded inconsistent results. In TAK, TNF inhibitors and tocilizumab are comparably effective; early data suggest Janus kinases (JAK) inhibitors promote remission, imaging improvement, and glucocorticoid sparing. Mavrilimumab (GM-CSF receptor blockade) is promising in GCA. Recent studies have increasingly focused on short-term glucocorticoid therapy in combination with biologic agents. Advances in biomarker research, including investigation of the IL-6 receptor and IL-17A gene polymorphisms, may enable more targeted therapeutic strategies. Key Points Giant cell arteritis (GCA) and Takayasu arteritis are both types of large vessel vasculitis, sharing common features but differing in aspects such as clinical presentation, underlying pathophysiology, and treatment response.Giant cell arteritis is an age-associated disease and has been linked to somatic mutations related to clonal haematopoiesis, including the TET2 gene.For both conditions, glucocorticoids remain the standard therapy, often combined with interleukin-6-receptor blockade, while Janus kinase inhibitors show particular promise in GCA. Recent studies have increasingly focused on short-term glucocorticoid therapy in combination with biologic agents specifically for GCA. Introduction Large vessel vasculitides (LVVs) are classified into two major entities according to the 2012 revised Chapel Hill Consensus Conference: Giant cell arteritis (GCA) and Takayasu arteritis (TAK) [1]. Giant cell arteritis is more common than TAK, but both diseases show marked geographical variation in incidence. A recent meta-analysis reported an overall annual pooled incidence of GCA of 10.0 cases per 100,000 individuals aged over 50 years with a high incidence in Scandinavia [2]. In contrast, TAK is much rarer, with a global annual pooled incidence of 0.11 cases per 100,000 individuals [3], with the highest rates reported in East Asian populations. Giant cell arteritis typically affects individuals aged > 50 years, with a peak incidence around the age of 75 years [4], whereas TAK generally manifests before the age of 40 years, with a median age of 25–30 years [5]. Both diseases demonstrate a female predominance: In GCA, the female-to-male ratio is approximately 2–3:1, while in TAK, it ranges from 6:1 to over 9:1 [6]. Clinically, GCA often affects cranial arteries and presents with cranial ischaemic symptoms such as headache, scalp tenderness, jaw claudication, and visual disturbances, including anterior ischaemic optic neuropathy, which can lead to blindness. However, large vessels such as the thoracic aorta and its proximal branches may also be affected, which can result in complications such as claudication and aneurysm formation. Notably, approximately 60% of GCA patients have concomitant polymyalgia rheumatica (PMR), supporting the concept of a disease spectrum rather than two isolated diseases [7]. Mendelian randomisation analysis of single-nucleotide polymorphism (SNP) indicated potential causal relationship between GCA and PMR at the genetic level, supporting the concept of the disease spectrum [8, 9]. Takayasu arteritis usually begins with non-specific systemic symptoms followed by vascular complications due to large artery involvement of different parts of the aorta and its branches. These include pulselessness, blood pressure discrepancies, renovascular hypertension, and stenoses or occlusions of affected arteries [10]. Both conditions have high relapse rates [11, 12]. Risk factors for relapse in GCA include female sex and large-vessel involvement [11]; in TAK, male sex, elevated C-reactive protein (CRP), and carotidynia have been identified [12]. Glucocorticoids (GC) are the mainstay of treatment for both diseases; however, a deeper understanding of the pathogenesis of LVV has led to the emergence of novel therapeutic approaches [13]. This narrative review delineates recent advances in disease pathogenesis alongside emerging therapeutic strategies based on these insights. While a formal systematic search strategy was not employed, the literature was comprehensively surveyed through key databases and recent relevant publications to provide a balanced and current overview. Pathophysiology and Rationale for Targeted Therapies Giant cell arteritis and TAK share similar pathophysiological features with CD4⁺ T cell, monocyte and macrophage infiltration in the arterial walls. Importantly, both diseases exhibit the presence of B cells and plasma cells within these inflammatory infiltrates, contributing to the complex immune landscape underlying vascular inflammation [13, 14]. Inflammation involving the adventitia, media, and intima promotes a vascular remodelling process in the affected arteries [15]. In both diseases, CD4⁺ T cells play a crucial role in promoting and sustaining inflammation, as well as in the formation of prototypic granulomas through macrophage differentiation. The CD4⁺ T cells differentiate into interferon-γ-producing Th1 cells and interleukin-17-producing Th17 cells [16]. In contrast to GCA, where CD4⁺ T cells play a central role, TAK involves both CD4⁺ and CD8⁺ T cells, with a higher abundance of CD8⁺ T cells, a reduced CD4⁺/CD8⁺ ratio, and increased numbers of CD20⁺ B cells compared to GCA [17]. The underlying pathophysiology provides the rationale for targeted therapies, which will be outlined in the following section (see Fig. 1 and Table 1). Pathophysiological mechanisms as a rationale for targeted therapeutic strategies. Immunological mediators of inflammation in large-vessel vasculitis and their therapeutic targets. Differentiation of T cells into Th1 and Th17. Dendritic cells interact with T cells and contribute to cytokine production. Macrophages are key contributors to pro-inflammatory cytokine production and the propagation of inflammatory cascades. Arrows highlighted in green denote therapeutic targets specific to giant cell arteritis, those highlighted in yellow represent targets specific to Takayasu arteritis, and arrows highlighted in blue indicate shared therapeutic targets implicated in both vasculitides. CD cluster of differentiation, GM-CSF granulocyte macrophage-colony stimulating factor, HLA human leukocyte antigen, IFN interferon, IL interleukin, JAK Janus kinase, TCR T-cell receptor, Th T helper, TNF tumour necrosis factor. Figure adapted from illustrations obtained from the NIAID NIH BioArt Source (bioart.niaid.nih.gov/bioart) Table 1Main immunopathophysiological pathways and key study findings in giant cell arteritis and Takayasu arteritisPathophysiologic targetDiseasePathophysiologic rationaleEfficacy highlights of selected clinical trialsIL- 6 receptor inhibitionGCAElevated levels of IL-6 and soluble IL-6 receptor are associated with active disease [18, 116]RCT Phase IIIFollow-up: 52 months251 treatment-naive and relapsing patientsMain result: TCZ+GC taper significantly increased sustained remission rates compared to placebo+GC taper [54]TAKIL-6 levels correlate with disease activity and relapse risk [21, 22]RCT Phase III plus open-label extension studyFollow-up: 96 weeks36 relapsing/refractory patientsMain result: TCZ delayed time to relapse compared to placebo, but not significantly [87]GC-sparing effect and improvements in well-being were observed during the extension study [88]JAK/STAT inhibitionGCAUpregulation of pathways linked to pro-inflammatory cytokines and chemokines, type I interferon, and JAK/STAT signalling, in GCA [28]RCT Phase IIIFollow-up: 52 weeks209 treatment-naive and relapsing patientsMain result: Upadacitinib showed superiority over placebo in achieving sustained remission in GCA [61]TAKUpregulation of genes involved in type I and II interferon responses, JAK/STAT signalling, and cytokine/chemokine pathways [29]Prospective studyFollow-up: 12 months67 relapsing patientsMain result: Tofacitinib demonstrated similar efficacy and safety compared to leflunomide combined with GC in TAK [91]IL-17 pathway blockadeGCAIncreased numbers of Th17 cells and IL-17-producing cells have been detected across all layers of affected temporal arteries [16]Level of IL-17 expression correlates directly with the intensity of the systemic inflammatory response [34]RCT Phase IIFollow-up: 28 weeks65 treatment-naive and relapsing patientsMain result: Secukinumab showed efficacy in maintaining remission with a favourable safety profile compared to placebo [63]TAKIL-17A correlates with disease activity [30, 36]Open-label cohort studyFollow-up: 6 months53 relapsing patientsMain result: Secukinumab demonstrated comparable efficacy and safety to TNF inhibitors in treating TAK [94]TNF alpha inhibitionGCATNF-α is present in inflammatory infiltrates but is not the dominant pathogenic cytokine [37]RCT Phase IIIFollow-up: 6 months70 newly diagnosed patientsMain result: Adalimumab + GC did not increase the number of patients in remission on less than 0.1 mg/kg of GC at 6 months [69]TAKTNF-α is produced by CD8⁺ T cells, natural killer cells, and macrophages, playing a central role in sustaining vascular inflammation and disease activity [38, 39]Open-label randomised studyFollow-up: 12 months40 relapsing/active patientsMain result: Adalimumab plus GC and MTX showed higher efficacy at 6 months compared to TCZ plus GC and MTX [85.7% vs 52.6%, p = 0.02], but no significant difference at 9 and 12 months [102]GM-CSF pathway inhibitionGCAIncreased GM-CSF and GM-CSF receptor-α mRNA and protein expression level has been demonstrated in GCA lesions [40]RCT Phase IIFollow-up: 6 months70 treatment-naive and relapsing patientsMain result: Mavrilimumab significantly reduced the risk of flare. Sustained remission at Week 26 was achieved in 83% of patients receiving mavrilimumab versus 50% in the placebo group [70]TAK–No clinical trialsGC glucocorticoid, GCA giant cell arteritis, GM-CSF granulocyte-macrophage colony-stimulating factor, IL-17 interleukin 17, JAK Janus kinase, RCT randomised controlled trials; m months, mRNA messenger RNA, STAT signal transducer and activator of transcription, TAK Takayasu arteritis, TCZ tocilizumab, Th T helper, TNFi tumour necrosis factor inhibitor Main immunopathophysiological pathways and key study findings in giant cell arteritis and Takayasu arteritis RCT Phase III Follow-up: 52 months 251 treatment-naive and relapsing patients Main result: TCZ+GC taper significantly increased sustained remission rates compared to placebo+GC taper [54] RCT Phase III plus open-label extension study Follow-up: 96 weeks 36 relapsing/refractory patients Main result: TCZ delayed time to relapse compared to placebo, but not significantly [87] GC-sparing effect and improvements in well-being were observed during the extension study [88] RCT Phase III Follow-up: 52 weeks 209 treatment-naive and relapsing patients Main result: Upadacitinib showed superiority over placebo in achieving sustained remission in GCA [61] Prospective study Follow-up: 12 months 67 relapsing patients Main result: Tofacitinib demonstrated similar efficacy and safety compared to leflunomide combined with GC in TAK [91] Increased numbers of Th17 cells and IL-17-producing cells have been detected across all layers of affected temporal arteries [16] Level of IL-17 expression correlates directly with the intensity of the systemic inflammatory response [34] RCT Phase II Follow-up: 28 weeks 65 treatment-naive and relapsing patients Main result: Secukinumab showed efficacy in maintaining remission with a favourable safety profile compared to placebo [63] Open-label cohort study Follow-up: 6 months 53 relapsing patients Main result: Secukinumab demonstrated comparable efficacy and safety to TNF inhibitors in treating TAK [94] RCT Phase III Follow-up: 6 months 70 newly diagnosed patients Main result: Adalimumab + GC did not increase the number of patients in remission on less than 0.1 mg/kg of GC at 6 months [69] Open-label randomised study Follow-up: 12 months 40 relapsing/active patients Main result: Adalimumab plus GC and MTX showed higher efficacy at 6 months compared to TCZ plus GC and MTX [85.7% vs 52.6%, p = 0.02], but no significant difference at 9 and 12 months [102] RCT Phase II Follow-up: 6 months 70 treatment-naive and relapsing patients Main result: Mavrilimumab significantly reduced the risk of flare. Sustained remission at Week 26 was achieved in 83% of patients receiving mavrilimumab versus 50% in the placebo group [70] GC glucocorticoid, GCA giant cell arteritis, GM-CSF granulocyte-macrophage colony-stimulating factor, IL-17 interleukin 17, JAK Janus kinase, RCT randomised controlled trials; m months, mRNA messenger RNA, STAT signal transducer and activator of transcription, TAK Takayasu arteritis, TCZ tocilizumab, Th T helper, TNFi tumour necrosis factor inhibitor The Interleukin 6 Pathway Interleukin-6 (IL-6) is produced by macrophages, monocytes and vascular dendritic cells and infiltrates T cells, promoting CD4⁺ T-cell proliferation within the arterial wall in GCA patients [18]. Elevated levels of IL-6 are associated with active disease [19, 20]. Similarly, IL-6 has a central role in TAK, where it is produced by macrophages and Th17 cells in the arterial wall. Interleukin-6 contributes to inflammation and subsequent fibrosis through activation of adventitial fibroblasts and promotion of extracellular matrix production. In TAK, IL-6 levels also correlate with disease activity and relapse risk [21, 22]. Despite the pivotal role of IL-6 in GCA and TAK, there remains a substantial proportion of patients who fail to achieve clinical remission under IL-6-receptor inhibition [23, 24]. One potential contributing factor is a common coding single nucleotide polymorphism (SNP) in the IL-6 receptor gene, p.Asp358Ala (rs2228145 A>C), which can modulate leukocyte responsiveness to IL-6. This polymorphism is present in approximately 30%–40% of the general population and leads to increased levels of soluble IL-6 receptor (sIL-6R). Zorc et al. [25] demonstrated that the rs2228145 variant is associated with a reduced response to IL-6 receptor blockade and poorer clinical outcomes in GCA, likely driven by enhanced IL-6 signalling in CD4⁺ T cells. These findings suggest that the rs2228145 variant could potentially be used as a biomarker to guide treatment decisions in GCA. Its role in TAK is unclear. The Janus Kinase/Signal Transducer and Activator of Transcription Pathway Janus kinases (JAK) are intracellular tyrosine kinases that bind to cytokine receptors and, upon receptor activation, transmit signals by phosphorylating signal transducer and activator of transcription (STAT) proteins [26]. Interferons activate the JAK/STAT pathway, leading to the transcription of interferon-stimulated genes (ISGs) that have immunomodulatory functions [27]. Vieira et al. [28] showed an upregulation of pathways linked to type I interferon, JAK/STAT signalling, pro-inflammatory cytokines and chemokines in GCA. Furthermore, type I IFN signature genes, STAT1 and STAT2 were significantly upregulated in patients with GCA and INF-α serum concentrations were higher in patients with active symptoms of GCA as compared with patients without symptoms. In a study involving 25 patients with TAK, transcriptome analyses demonstrated that CD4+ and CD8+ T cells showed significant upregulation of genes involved in type I and II interferon responses, JAK/STAT signalling, and cytokine/chemokine pathways [29]. This dysregulation promotes the differentiation of naive CD4+ T cells to pro-inflammatory Th1 and Th17 cells in blood and is associated with disease activity and production of IFNγ and IL-17 [30]. The Interleukin-17 Pathway Interleukin-17 (IL-17) is a proinflammatory cytokine mainly produced by Th17 cells as well as CD8+ T cells, γδ T cells, and various innate immune cell populations [31]. I-17-mediated inflammation is normally regulated by regulatory T cells and anti-inflammatory cytokines such as IL-10, transforming growth factor-β (TGF-β), and IL-35. However, dysregulation of IL-17 responses can contribute to immunopathology in autoimmune settings [32]. In active GCA, increased numbers of Th17 cells and IL-17-producing cells have been detected across all layers of affected temporal arteries [16]. Expansion of the Th17 population in the peripheral blood of GCA patients is accompanied by decreased regulatory T cell (Treg) numbers [33]. Interleukin-17 and IL-17 receptor expression are markedly upregulated in GCA arteries exhibiting transmural inflammation, and the level of IL-17 expression correlates directly with the intensity of the systemic inflammatory response [34]. A meta-analysis including over 1000 patients demonstrated that polymorphisms within the IL-17A locus (SNPs rs2275913, rs4711998, and rs7747909) are associated with susceptibility to GCA compared with healthy controls [35]. In TAK, IL-17A correlates with disease activity [30, 36]. The TNF-Alpha Pathway In GCA tumour necrosis factor-α (TNF-α) is consistently detectable within inflammatory infiltrates; however, it does not represent the dominant effector cytokine driving disease pathology [37]. In TAK, the inflammatory infiltrate is characterised by an increased contribution of CD8⁺ T cells and natural killer cells, which represent important additional cellular sources of TNF-α alongside activated macrophages. Consequently, TNF-α emerges as a key pathogenic cytokine in TAK, amplifying pro-inflammatory signalling cascades and playing a central role in the maintenance of vascular inflammation and disease activity [38, 39]. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multifunctional cytokine that regulates the biology of CD4⁺ T cells and dendritic cells and plays a central role in macrophage maturation and function. Increased GM-CSF and GM-CSF receptor-α expression in mRNA and protein level has been demonstrated in GCA lesions [40]. Within the inflamed arterial wall of patients with GCA, GM-CSF is produced by multiple cell types, including B cells, fibroblasts and T cells. Granulocyte-macrophage colony-stimulating factor drives the differentiation and activation of pro-inflammatory macrophage subsets, particularly CD206⁺MMP-9⁺ macrophages, which mediate tissue destruction and folate-receptor-β⁺ macrophages (FRβ⁺), which promote intimal proliferation [41]. Adventitial CD90⁺ fibroblasts have been shown to express both GM-CSF and M-CSF, linking fibroblast activity to the distribution of distinct macrophage subsets. This GM-CSF-dependent crosstalk between macrophages and fibroblasts may contribute to the chronicity and progression of GCA [42]. The PD-1/PD-L1 Checkpoint Pathway New-onset GCA has been observed following immune checkpoint inhibitor (ICI) therapy, with a reported prevalence of 0.06% among ICI-treated patients [43]. In this context, Monjo et al. [44] investigated the role of the programmed cell death 1/programmed cell death-ligand-1 (PD-1/PD-L1) co-inhibitory pathway in the pathogenesis of GCA. In this prospective study including 65 patients with newly diagnosed GCA, the authors assessed the frequency of circulating T peripheral helper (cTph) and T follicular helper (cTfh) cells – two CD4⁺ T cell subsets known to be associated with autoimmunity. The study demonstrated increased frequencies of both cTph and cTfh cells in patients with active GCA. Notably, both subsets exhibited high expression of PD-1, which may reflect a compensatory counter-regulatory mechanism. Patients who experienced disease relapse showed significantly lower frequencies of these cell populations compared to those in sustained remission. This suggests that an insufficient capacity to upregulate the PD-1 checkpoint pathway is associated with a poorer prognosis, further supporting a functional role of the PD-1/PD-L1 axis in the pathogenesis of GCA. Molecular and Genetic Factors Molecular Signatures of GCA and TAK Revealed by Omics Studies Recent omics studies have provided important mechanistic insights into GCA and TAK [45]. Plasma proteomic profiling across the LVV spectrum demonstrated shared inflammatory and stromal remodelling signatures in GCA and TAK, including IL-6, monocyte/macrophage-associated proteins (e.g. CCL7, CSF1), tissue remodelling proteins (TIMP1, TNC), and novel mediators such as TNFSF14 and IL-7R, supporting overlapping innate immune activation despite clinical heterogeneity. Multi-omics analyses in GCA identified Unc-51 like kinase 3 (ULK3) as the strongest protective factor via regulation of autophagy, highlighting its potential role in disease modulation [46]. Additionally, SLAMF7 was recognised as a potential target of elotuzumab. Among the identified targets, five (SLAMF7, ICAM1, IL18, IL6ST, CTSS) already have approved therapeutics. Single-cell analyses showed disrupted gene-immune cell interactions and cell-type-specific inflammatory gene expression in untreated GCA, with TYMP identified as the key hub gene. In TAK, integrated bulk and single-cell transcriptomic profiling of peripheral T-cell subsets from eight treatment-naive patients and aortic tissue from three patients revealed shared signatures involving cytokine signalling, complement activation, focal adhesion, and extracellular matrix organisation, alongside subset-specific patterns [47]. In CD4⁺ differentially expressed genes (DEGs) were enriched for inflammation, angiogenesis, and platelet activation, whereas CD8⁺ DEGs were linked to cytokine synthesis, notably interleukin-1 signalling. The transcription factor EGR1 was consistently identified in both blood and tissue, underscoring its pivotal role in systemic and vascular inflammation. These omics studies delineate shared and disease-specific molecular signatures in GCA and TAK and provide a foundation for biomarker development and precision-targeted therapies in LVV. Genetic Risk Factors in the Pathogenesis of GCA and TAK Genome-wide association studies (GWAS) have provided important insights into the pathogenesis of inflammatory rheumatologic diseases. In GCA, susceptibility loci have been primarily identified in the human leukocyte antigen (HLA) region on chromosome 6, which confer an increased risk of disease development [48]. In TAK, HLA-B*52 has been confirmed as a major susceptibility allele, alongside four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chromosome 13q21. Additionally, IL12B, PTK2B, and a locus on chromosome 21q22 have been confirmed as susceptibility regions [49]. Further, two tag SNPs in the promoter region of IL-18 (rs187238 and rs1946518) and one 3'UTR tag SNP in FGF2 (rs1476217) have been significantly associated with susceptibility to TAK, suggesting their potential role as risk factors for the development of TAK [50]. Somatic Mutation in the Pathogenesis of GCA and TAK Beyond these genetic variations somatic mutations leading to activation of the myeloid cell compartment play a role in GCA pathogenesis. Clonal haematopoiesis (CH), characterised by the expansion of haematopoietic stem cell clones with somatic mutations, can arise due to aging and chronic inflammation. Giant cell arteritis is an age-associated disease, with cumulative incidence increasing significantly in patients harbouring clonal haematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS). Among the somatic mutations studied, alterations in the Tet methylcytosine dioxygenase 2 (TET2) gene, which encodes an epigenetic regulator, have been associated with an increased risk of developing GCA and are linked to cases complicated by ischaemic vision loss [48, 51]. Gutierrez et al. [52] investigated the prevalence and functional relevance of CH in patients with GCA and TAK compared to age-matched healthy controls. The incidence of CH was found to be 13% in TAK and markedly higher at 61% in GCA. The most frequently mutated gene was DNA methyltransferase 3 alpha (DNMT3A), followed by TET2. Somatic mutations with a variant allele frequency (VAF) ≥10% were also observed exclusively in older individuals, most commonly in those diagnosed with GCA. Clonal haematopoiesis was significantly more common in patients with GCA compared to age-matched healthy controls. Moreover, patients with CH had a higher risk of disease relapse compared to GCA patients without CH (67% vs 25%, p < 0.01). Overview of Current Targeted Therapies Several new therapeutic approaches for the treatment of LVV have emerged in recent years. Glucocorticoids (GCs) remain the mainstay for initial treatment of GCA and TAK, with a strategy of slow tapering. However, relapse rates remain high under GC monotherapy and the prolonged treatment duration increases the risk for GC-associated adverse events. Therefore, research has been focusing on the efficacy of immunomodulatory agents to improve clinical outcomes and reduce GC cumulative doses (see Table 1). Therapeutic Approaches in GCA According to the 2018 EULAR recommendations for the management of LVV, induction of remission in GCA should begin with GC therapy (40–60 mg/day prednisone-equivalent) [53]. In cases with acute visual loss or amaurosis fugax, the administration of 250–1000 mg/d intravenous (IV) methylprednisolone for up to three days should be considered. The 2021 ACR guidelines conditionally recommend the use of oral GCs in combination with tocilizumab (TCZ), rather than oral GC alone, for patients with newly diagnosed GCA [13], while EULAR recommendations suggest using TCZ as an add-on in newly diagnosed cases with a high risk of GC-related adverse events or comorbidities, or in patients who experience relapses. IL-6 Receptor Inhibiton The GiACTA trial represents a landmark in the management of GCA as the first randomised, double-blind, placebo-controlled Phase III trial. The study involved 251 patients with GCA evaluating TCZ administered weekly or every other week in combination with a 26-week GC taper, compared with placebo combined with either a 26- or 52-week GC tapering regimen [54]. At Week 52, sustained remission (flare free from Week 12 to 52, normalised CRP with protocol GC taper adherence) was achieved in 56% of patients on weekly TCZ and 53% on every-other-week TCZ, compared with 14% and 18% in the placebo groups with 26- and 52-week GC tapers, respectively (p < 0.001). The cumulative median GC dose over 52 weeks was 1862 mg in both TCZ groups versus 3296 mg (placebo 26-week taper) and 3818 mg (placebo 52-week taper; p < 0.001 for both). Several other studies have investigated the impact of TCZ on GC tapering strategies in GCA. In a prospective, single-arm, open-label study by Unizony et al. [55], the efficacy of TCZ in combination with a short 8-week GC taper was evaluated in 30 patients with new-onset or relapsing GCA. Sustained GC-free remission at Week 52 was achieved in 23 patients (77%) and seven patients (23%) relapsed (mean time to relapse:15.8 weeks [SD 14.7]). A recent prospective observational study (TOPAZIO) evaluated the impact of an ultra-short GC pulse regimen (IV methylprednisolone 500 mg/day for 3 days) followed by weekly TCZ for 52 weeks in 18 patients with large-vessel GCA [56]. The primary endpoint, a reduction in PET vascular activity score (PETVAS) at Weeks 24 and 52 was met (mean change (95% CI) − 8.6 (− 11.5 to − 5.7) at Week 24 and − 10.4 (− 13.6 to − 7.2) at Week 52; p = 0.001 and 0.002), respectively. In a 26-week observational follow-up after TCZ discontinuation, received TCZ monotherapy was effective in maintaining drug-free clinical remission in large-vessel GCA, with sustained PETVAS reduction compared to baseline; however, PETVAS significantly increased six months after TCZ discontinuation (mean [95% CI] change from Week 52 to 78: + 4.6 [0.7–8.5]) suggesting inflammatory activity [56]. It should be noted that the study excluded patients with cranial symptoms, limiting generalisation of these results to standard clinical practice in GCA. Accordingly, such abbreviated GC-TCZ protocols should currently be restricted to controlled clinical studies at specialised centres with appropriate expertise. Another study (GUSTO trial) investigated TCZ monotherapy following ultra-short GC administration (500 mg IV methylprednisolone for three days) in new-onset GCA in a single-arm, open-label, proof-of-concept trial. In contrast to the TOPAZIO study [57], which included only patients without ischaemic cranial manifestations, 15 of the 18 enrolled patients in this trial presented with cranial involvement. Remission was achieved in 14 (78%) of 18 patients within 24 weeks; with a relatively long mean time to remission (11.1 weeks [95% CI 8.3-13.9]). Thirteen of 18 (72%) patients remained relapse-free up to Week 52 (95% CI 47–90), while 3 of 18 patients were considered primary treatment failures. Concerningly, one patient developed anterior ischaemic optic neuropathy [58]. In the extension study [59] drug-free remission was maintained in most patients. At Week 52, 13 of 18 patients were in relapse-free remission. Minor relapses occurred in two patients at Weeks 72, 187, and 200, both regaining remission after restarting TCZ monotherapy. By Week 208, 11 of 18 patients remained in relapse-free remission, with 11 of 13 maintaining drug-free remission for 156 weeks. In a retrospective cohort study by Nielsen et al. [60], which included 155 patients with GCA, relapse rates were compared between tapering and abrupt discontinuation strategies of TCZ. Tocilizumab was primarily initiated due to relapse in 100 of 155 patients (65%). Among the 104 patients who discontinued TCZ, 59% stopped the drug abruptly, 46% of whom experienced a relapse during follow-up (median overall follow-up duration: 854 days from diagnosis and 572 days from TCZ initiation). In contrast, 57 patients underwent tapering, with relapse occurring in 16% (6/38) of those tapering every 2 weeks and in 11% (2/19) of those tapering every 3 weeks. Most relapses (88%; 42 of 48) occurred during the first year of follow-up. Tocilizumab tapering was associated with significantly longer relapse-free survival compared to abrupt discontinuation (p = 0.02). However, relapse rates after discontinuation of treatment were similar between slow and rapid TCZ tapering (21 of 45 [47%] vs 27 of 59 [46%]), respectively. Interleukin-6-receptor blockade represents an effective and well-tolerated therapeutic option in GCA and is incorporated into international treatment guidelines. Despite this, high relapse rates following discontinuation of IL-6-receptor blockade remain a significant challenge. Further studies are therefore needed to clarify its role in facilitating a standardised GC-tapering regimen in routine clinical practice. JAK/STAT Inhibition In the Phase III, randomised, multicentre, double-blind, placebo-controlled SELECT-GCA trial, Blockmans et al. [61] evaluated the efficacy and safety of the JAK inhibitor upadacitinib (15 mg/d and 7.5 mg/d) in combination with a 26-week GC taper, compared to placebo plus a 52-week GC taper, in patients with new-onset or relapsing GCA. A total of 428 patients were enrolled: 209 received upadacitinib 15 mg, 107 received upadacitinib 7.5 mg, and 112 received placebo. The primary endpoint, sustained remission at Week 52 (absence of GCA symptoms Weeks 12–52 with protocol GC taper adherence) was achieved more frequently in upadacitinib 15 mg than placebo (46.4% [95% CI 39.6–53.2] vs 29.0% [95% CI 20.6–37.5]; p = 0.002). Additionally, secondary endpoints including sustained complete remission (defined as sustained remission with normalised ESR and CRP from Weeks 12 to 52), time to disease flare, cumulative GC exposure, and patient-reported outcomes were favouring upadacitinib 15 mg. In contrast, upadacitinib 7.5 mg did not demonstrate superiority for the primary endpoint compared to placebo (41.1% [95% CI 31.8–50.4]). In a small prospective, open-label pilot study over 52 weeks, baricitinib was investigated in patients with relapsing GCA [62]. During the observation period, only 1 out of 14 patients (7%) experienced a relapse, while the remaining patients maintained remission under baricitinib, even after GC discontinuation. Therefore, both studies have demonstrated the efficacy of JAK inhibitors, significantly broadening the therapeutic options available in this area. IL-17 Pathway Blockade In a randomised, double-blind, placebo-controlled, multicentre Phase II trial (TitAIN), a total of 52 patients with new-onset or relapsing GCA were enrolled and randomised to receive either secukinumab (n = 27) or placebo (n = 25), both in combination with a standardised 26-week GC tapering regimen. The proportion of patients achieving sustained remission at Week 28 (flare free Weeks 12–28, adherence to the GC taper) was significantly higher in the secukinumab group compared to the placebo group (70% [95% credibility interval, 52–85] vs 20% [12–29]). No new safety signals were identified [63]. However, the following Phase III trial (GCAptAIN) did not meet its primary endpoint sustained remission in Week 52 in adults with newly diagnosed or relapsing GCA as communicated by the sponsor of the trial [64]. While all three studies (GIACTA, SELECT-GCA and GCAptAIN) had sustained remission in Week 52 as the primary endpoint, the definition of sustained remission in GCAptAIN significantly differed from the definitions used in SELECT-GCA. Also, the less pronounced effect of secukinumab on CRP-concentrations that were part of the definition of the primary endpoint, might have contributed to the study outcome. Detailed trial data of the GCAptAIN study have not yet been published. However, a small case series of six patients refractory to TCZ demonstrated clinical and imaging remission. Thus, despite the failure to meet the primary endpoint in the GCAptAIN TITAN study, a potential role for IL-17 blockade cannot be excluded [65]. Additionally, as is well established, PMR and GCA represent a disease spectrum [9]. In patients with PMR treated with secukinumab in the randomised controlled REPLENISH trial, the primary endpoint of sustained remission at Week 52 was met, as reported by the study sponsor [66]. TNF-α Inhibition Several randomised controlled trials investigating TNF inhibitors, including infliximab, etanercept, and adalimumab, have consistently failed to demonstrate significant clinical benefit or GC-sparing effects in GCA [67–69]. These findings suggest that TNF blockade is not an effective therapeutic strategy in GCA. GM-CSF Pathway Inhibition Mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor, was evaluated in a Phase II randomised, double-blind, placebo-controlled, multicentre trial in patients with new-onset or relapsing GCA [70]. A total of 70 patients were enrolled (42 received mavrilimumab, 28 received placebo), each in combination with a 26-week GC taper. Mavrilimumab significantly reduced the risk of flare compared with placebo (flare: 19% vs 46%). The primary outcome median time to flare was 25.1 weeks in the placebo group but could not be calculated for patients in the mavrilimumab group because fewer than 50% experienced a flare during the 26 weeks (HR 0.38; 95% CI 0.15–0.92; p = 0.026). Despite these promising results, a Phase III trial has not yet been conducted. Other Cytokine and Immune Targets In a multicentre trial, 49 patients with GCA were treated with IV abatacept (a fusion protein that inhibits T-cell activation by blocking costimulatory signals), 10 mg/kg on Days 1, 15, 29, and Week 8, alongside daily GC [71]. At Week 12, patients in remission were randomised in a double-blind manner to continue monthly abatacept or switch to placebo, with both groups following a standardised GC taper ending at Week 28. Abatacept significantly reduced the risk of relapse, with a relapse-free survival rate at 12 months of 48% in the abatacept group versus 31% in the placebo group (p = 0.049). Although a prospective, open-label 52-week study by Conway et al. [72] demonstrated that ustekinumab, an IL-12/23 inhibitor, may be a promising treatment option, as 25 patients with refractory GCA showed sustained disease control until Week 52, another prospective trial [73] evaluating ustekinumab in 13 patients with active new-onset or relapsing GCA reported a low rate of GC-free remission at Week 52 (23%), defined as absence of relapse and normalisation of ESR and CRP. The THEIA Phase II trial, which investigated guselkumab, a selective IL-23 blockade, in combination with a 26-week GC taper versus placebo for the treatment of new-onset or relapsing GCA, recently reported that the primary endpoint, GC-free remission, was not significantly different between the treatment arms, leading to termination of the study due to insufficient efficacy, with no new safety signals identified [74]. Three randomised, double-blind, placebo-controlled trials compared methotrexate (MTX) plus GC with placebo plus GC in GCA. Two trials found no significant advantage of MTX [75, 76], whereas one trial demonstrated a reduced risk of relapse in the MTX group [77]. A meta-analysis of these three trials with 161 patients with newly diagnosed GCA (MTX, n = 84; placebo n = 77) was performed [78]. Mean follow-up was 54.7 weeks (SD 39.2), and MTX doses ranged from 7.5–15 mg/week. Methotrexate significantly reduced the risk of first and second relapse compared to placebo, respectively (HR 0.65, 95% CI 0.44–0.98, p = 0.04; and HR 0.49, 95% CI 0.27–0.89, p = 0.02). The number-needed-to-treat (NNT) to prevent one first or second relapse within 48 weeks was 3.6 (95% CI 2.2–56.8) and 4.7 (95% CI 3.3–21.9), respectively. Methotrexate also reduced cumulative prednisolone dose by 842 mg over 48 weeks (p < 0.001). The abstract of the MetoGIA study, an open-label, randomised, controlled, multicentre non-inferiority trial, was recently presented as preliminary data at the ACR 2025 meeting [79]. Among 218 patients (MTX n = 108; TCZ n = 110), the primary endpoint, defined as the proportion of patients without relapse after initial remission and without deviation from the GC taper from baseline to Week 78, was achieved in 37% (MTX) versus 46% (TCZ), corresponding to a 9% difference (95% CI −4% to 22%); thus, MTX did not demonstrate non-inferiority to TCZ. Leflunomide has been investigated in several studies involving patients in GCA. In a prospective, open-label study, leflunomide was evaluated in 215 patients [80]. At Week 12, 151 patients received leflunomide and GC, while the remaining patients continued GC monotherapy. During the 96-week follow-up, 64 patients (29.8%) experienced a relapse. Among the 51 patients who relapsed after Week 12, 22 of 151 (14.6%) in the leflunomide group versus 29 of 64 (45.3%) in the GC-only group relapsed (p = 0.001; NNT 3.3 for leflunomide). A 2-year follow-up study in an Indian cohort (n = 22) demonstrated that leflunomide effectively reduced GC exposure while maintaining disease control [81]. Additionally, an open-label study showed a GC-sparing effect of leflunomide plus GC compared to GC monotherapy, with significantly fewer relapses during 48 weeks of follow-up (13.3% vs 39.1%, p = 0.02) [82]. Therapeutic Approaches in TAK Although the initial GC regimen in TAK closely parallels that of GCA, the clinical course of TAK is often more refractory in terms of delayed treatment response and relapse risk. High relapse rates combined with the frequent challenges of GC tapering and the risk of vascular complications, underscore the need for early initiation of immunosuppressive therapy. According to the 2021 American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the Management of TAK, non-GC immunosuppressive agents such as MTX, azathioprine, and tumour necrosis factor inhibitors (TNFi) may be used in combination with GC [13]. In cases of inadequate response, the use of TCZ is recommended. Randomised controlled trials are limited, and the available evidence remains relatively sparse. As a result, current recommendations are based on low to very low levels of evidence [13, 53]. IL-6 Receptor Inhibiton Several retrospective and prospective studies have demonstrated the efficacy and safety of IL-6 receptor inhibition [83–86]. A randomised, double-blind, placebo-controlled Phase III trial (n = 36) in patients with TAK did not achieve the primary endpoint; however, a benefit of TCZ in terms of prolonged time to relapse was observed [87]. Long-term efficacy and a GC-sparing effect without new safety concerns were further confirmed in the open-label extension of this study [88]. Furthermore, in a prospective multicentre open-label study, patients received seven infusions of TCZ followed by a 12-month observation period after treatment cessation [89]. During this follow-up, 45% of patients experienced relapse, suggesting that although TCZ is effective, ongoing maintenance therapy may be necessary. Further research is needed to establish the optimal duration of IL-6-receptor blockade. In a single-centre retrospective analysis of 63 patients by Liao et al. [90], the disease activity of patients treated with TCZ (n = 31) was lower compared to cyclophosphamide-treated patients (n = 32) (NIH score <1 in TCZ: 50%, 90%, and 96% at 1, 3, and 6 months vs cyclophosphamide: 36%, 30%, and 78%), respectively. Overall, evidence from clinical trials and observational studies supports TCZ as a safe and effective option for managing TAK, improving disease control and reducing cumulative GC dose. JAK/STAT Inhibition Recently published data demonstrated the efficacy of JAK inhibitors in the treatment of TAK. A prospective cohort study evaluated the efficacy and safety of tofacitinib versus leflunomide over 12 months [91]. A total of 67 patients were enrolled, with 35 patients in the leflunomide group and 32 in the tofacitinib group. Complete remission (CR) was defined as no new or worsening systemic or vascular symptoms, ESR ≤40 mm/h, and GC dose ≤15 mg/day at 6 months or ≤10 mg/day at 12 months. Partial remission (PR) required no new or worsening vascular symptoms plus at least two of the other criteria. The effectiveness rate (ER), which included patients who achieved CR or PR, was comparable between the groups (leflunomide 88.57% [31/35] vs tofacitinib 87.50% [28/32], p = 1.00). Furthermore, after 12 months, a significantly higher proportion of patients in the tofacitinib group was in sustained remission under low-dose GC (≤7.5 mg/day) (46.9% vs 17.1%, p = 0.02) and angiographic improvement was more frequent in the tofacitinib group (25.0% vs 5.7%, p = 0.04). In a prospective observational study involving 53 patients, tofacitinib combined with GC was compared to MTX plus GC over a 12-month observation period [92]. Complete remission rates were higher in the tofacitinib group compared to the MTX group at 12 months (88.46% vs 56.52%, p = 0.02). Furthermore, tofacitinib demonstrated a longer median relapse-free duration and a lower average GC dose. In a prospective cohort study, the efficacy of baricitinib in combination with GCs was evaluated in patients with refractory TAK [93]. A total of 10 patients received baricitinib. After 6 months, 60% (6/10) of patients achieved an overall treatment response, defined as a CRP level <10 mg/L, absence of angiographic disease progression, and a GC dose <15 mg/day. Four of these patients maintained their response during a median follow-up of 15.3 months (range 4–31). Overall, JAK inhibitors may represent a potential therapeutic option; however, further randomised controlled trials are needed to confirm these results. IL-17 Pathway Blockade A prospective, single-centre, open-label cohort study evaluated secukinumab versus TNFi in 53 patients with TAK who were refractory to treatment with GC combined with two conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or one csDMARD and TCZ. Nineteen patients received secukinumab and 34 patients were treated with TNF inhibitors. Complete response was defined as full clinical remission, normalisation of inflammatory markers, no arterial progression on imaging, and GC dose <15 mg/day. Comparable response rates were observed at 3 months (31.6% for secukinumab vs 58.8% for TNF inhibitors, p = 0.057) and at 6 months (52.6% vs 64.7%, p = 0.389), with similar safety profiles between the two treatment groups [94]. TNF-α Inhibition Several observational studies have demonstrated a meaningful improvement in disease activity in patients with TAK treated with TNF inhibitors [95–97]. Long-term follow-up studies confirmed that infliximab induced a sustained clinical improvement over time, accompanied by significant benefits in health-related quality of life [98–100]. More recently, a large retrospective multicentre study directly compared ADA (n = 34) and infliximab (n = 101) in patients with TAK [101]. This study confirmed that both TNF inhibitors are effective in routine clinical practice, with no significant differences observed between the two agents regarding the risk of relapse or the need for revascularisation procedures. Rates of complete response, defined as a National Institutes of Health (NIH) activity score < 2 with a prednisone dose < 7.5 mg/day, were comparable between groups, being achieved in 68% of patients treated with ADA and 73% of those receiving infliximab (p = 0.8). Comparison of TCZ with TNF inhibitors In a randomised controlled, open-label trial, the efficacy and safety of Adalimumab (ADA) versus TCZ were evaluated in patients with active and severe TAK [102]. A total of 40 patients were enrolled, with 21 receiving ADA and 19 receiving TCZ, both in combination with the same GC tapering schedule and MTX 15 mg/per week. The primary endpoint was the efficacy rate (ER) at 6 months, defined as a GC dose ≤ 15 mg/day without new or worsening systemic symptoms or vascular lesions upon imaging. In the intention-to-treat population, the ER at 6 months was significantly higher in the ADA group compared to the TCZ group (85.71% vs 52.63%, p = 0.02). Nevertheless, efficacy rates at 9 and 12 months did not differ significantly between the groups. However, it should be taken into account that a greater proportion of patients in the ADA group were treatment-naive compared to the TCZ group (28.57% vs 10.53%, respectively), and the median disease duration was approximately 14 months shorter [103]. Several other studies have demonstrated comparable outcomes between TCZ and TNFi, suggesting similar efficacy profiles in TAK. In a multicentre retrospective cohort study conducted across Europe, 209 patients with TAK treated with either TNFi (n = 132) or TCZ (n = 77) were included. At 6 months, CR, defined as National Instituted of Health (NIH) score < 2 and prednisone < 10 mg/day, was achieved in 66% (101/152) of patients receiving TNFi and 70% (75/107) of those treated with TCZ [104]. Similarly, the retrospective analysis by Alibaz-Oner et al. [105] involving 111 patients demonstrated that the efficacy of TNFi and TCZ was comparable in terms of remission rates. In contrast to the 2021 ACR recommendations [13], a systematic review and meta-analysis of six studies found no significant differences between TCZ and TNFi in clinical remission (RR 1.03, 95% CI 0.91–1.17), angiographic stabilisation (RR 1.00, 95% CI 0.72–1.40), or adverse events (RR 0.84, 95% CI 0.54–1.31), supporting broadly similar effectiveness of both biologic strategies in TAK [106]. Well-designed randomised controlled trials, including adequately powered head-to-head comparisons with standardised GC tapering and longer follow-up, are required to definitively clarify the relative efficacy and safety of TCZ versus TNFi in TAK. Other Cytokine and Immune Targets In a randomised controlled study including 34 patients with TAK, those who achieved remission under abatacept combined with a GC tapering schedule by Week 12 underwent double-blind randomisation to continue monthly abatacept or switch to placebo [107]. The addition of abatacept to GC did not reduce the risk of relapse compared with placebo (p = 0.853) and was not associated with a longer median duration of remission (abatacept: 5.5 months vs placebo: 5.7 months). Methotrexate has already demonstrated therapeutic efficacy in patients with TAK [108]. A retrospective multicentre study compared MTX and azathioprine (AZA) as initial GC-sparing therapies in patients with TAK. Of the 301 patients included, 204 received MTX and 77 received AZA [109]. No differences were seen with regard to remission rates, relapse frequency, radiographic progression (not defined in the manuscript), and drug survival. Higher rates of vascular surgery (AZA: 23% vs MTX: 9%, p = 0.001) were reported in the AZA group; however, higher frequencies of GC treatment in the MTX group and other methodological limitations (i.e., no information on the administered doses and outcomes) make conclusions difficult. Leflunomide has demonstrated efficacy and safety in TAK, with observational studies reporting clinical improvement and disease activity reduction [110, 111]. A retrospective cohort study by Peron et al. [112] compared the effectiveness and safety of ADA and leflunomide in patients with TAK. A total of 44 patients were included, with 28 receiving leflunomide and 16 receiving ADA. After 15 months, the two groups showed comparable outcomes (CR rate: 62.5% for ADA vs 78.3% for leflunomide; p = 0.307; development of new arterial lesions: 40% vs 25%; p = 0.467). A limitation is that more ADA patients needed baseline IV methylprednisolone, indicating greater disease severity. In comparison, a cohort study of 68 patients demonstrated that leflunomide achieved a faster treatment response and a significantly lower relapse rate compared to MTX over a 12-month follow-up period (7.24% vs 16.67%, p = 0.03) [113]. Additionally, in two prospective cohort studies (n = 131 and n = 929), leflunomide demonstrated superiority over cyclophosphamide in patients with TAK [114, 115]. Leflunomide appears to be a promising therapeutic target in TAK; however, randomised controlled trials are still needed. Therapeutic Pipeline and Ongoing Trials Ongoing Clinical Trials of GCA Several novel and known therapeutic strategies are under current investigation in GCA to improve remission maintenance and reduce GC exposure. In addition to therapies already under investigation in GCA, such as secukinumab (NCT05380453), abatacept (NCT04474847), ustekinumab (NCT03711448) and MTX (NCT05623592), novel agents including the endothelin receptor antagonist bosentan, are also being evaluated (NCT06957002, NCT06887062) (see Table 2 for details). Table 2Ongoing and recently completed clinical trials in giant cell arteritis and Takayasu arteritisInterventionNCT numberStudy designNo. participantsPopulationControlPrimary outcomeAnticipated primary completion dateGiant cell arteritisSecukinumab + GCNCT05380453 (GigAINt) (Phase III)Randomised, parallel-group, double-blind, placebo-controlled,multicenter study151Patients with new onset GCA (6 weeks) and clinical remission after initial treatmentPlacebo + GC taperingEvaluation of efficacy, safety and tolerability of secukinumab (Week 52)27-Feb-2026 (no final results posted)Bosentan + GCNCT06957002 (BOSICART) (Phase II)Multicentre, randomised, controlled study40Patient with GCAGC standard therapyEvaluation of the efficacy of bosentan (relapse rate, adverse events, relapse-free survival at 12 months)01-Sep-2029Bosentan + dapagliflozinNCT06887062 (DERAIL-LVV) (Phase II)Open-label study60Patients with LVVNAEvaluation of improvement in endothelial function at 6 weeks (forearm plethysmography)01-Jul-2027MTXNCT05623592 (MTXinGCA) (Phase II)Randomised, double-blind, placebo-controlled, parallel group study52Patients with GCA after remission induction with TCZ and GCPlaceboEvaluation of efficacy (relapse rate) (12 months)01-Nov-2025 (no results posted)AbataceptNCT04474847 (ABAGART) (Phase III)Randomised, double-blind, placebo-controlled study78Patients with newly diagnosed or relapsing GCAPlaceboEvaluation of efficacy (remission) (12 months)01-Dec-2029Ustekinumab + GCNCT03711448 (ULTRA) (Phase 2)Randomised, open-label study38Patients with relapsing refractory GCAGCEvaluation of the efficacy of ustekinumab (Week 52)11-Sep-2024 (no results posted)Takayasu arteritisUpadacitinib + GCNCT04161898 (SELECT-Takayasu Study) (Phase III)A multicentre, randomised, double-blind, placebo-controlled study56Patients with TAKPlacebo + GCEvaluation of efficacy (time to first relapse)01-Aug-2027DeucravacitinibNCT07013838 (TYK-TAK Trial) (Phase IV)Single-centre, randomised, open-label study50Patients with relapsing TAKAdalimumabEvaluation of efficacy and safety at Month 1, 3, 631-Mar-2027GC glucocorticoid, GCA giant cell arteritis, LVV large vessel vasculitis, MTX methotrexate, NA not applicable, TAK Takayasu arteritis Ongoing and recently completed clinical trials in giant cell arteritis and Takayasu arteritis Randomised, parallel-group, double-blind, placebo-controlled, multicenter study GC glucocorticoid, GCA giant cell arteritis, LVV large vessel vasculitis, MTX methotrexate, NA not applicable, TAK Takayasu arteritis Ongoing Clinical Trials of TAK The Phase III SELECT-Takayasu trial is evaluating upadacitinib in patients with active TAK (NCT04161898). Deucravacitinib, a selective TYK2 inhibitor targeting Th1/Th17 cytokines and type I interferon pathway, is tested against ADA in relapsing TAK (TYK-TAK trial) (NCT07013838) (see Table 2 for details). Conclusion Although GCA and TAK are both classified as LVV and share overlapping clinical features, they represent immunologically and therapeutically distinct entities. Common pathogenic pathways include IL-6, JAK/STAT/interferon, and IL-17 signalling. On the cellular level, GCA is characterised by GM-CSF-dependent macrophage subsets checkpoint dysregulation (PD-1/PD-L1), and age-associated clonal haematopoiesis (CH) of myeloid cells, whereas TAK exhibits dominance of CD8⁺ T cells, disturbance of TNF-α signalling, and a potential pivotal role of the transcriptional factor EGR1, identified through omics analyses. These divergent mechanisms provide a strong rationale for precision medicine approaches and targeted deployment of novel therapeutic classes. In GCA, IL-6-receptor blockade with TCZ remains first-line therapy, with JAK inhibitors emerging as valid alternatives for patients with inadequate response or intolerance. The GM-CSF receptor blockade (e.g., mavrilimumab) shows promising efficacy but requires further validation. For TAK, current evidence supports the use of both TNF inhibitors and TCZ as effective biologics, despite ACR recommendations favouring IL-6-receptor blockade; TNF inhibitors may serve as important options for refractory cases. In both diseases, biologics primarily aim to minimise cumulative GC exposure, addressing a major source of morbidity. Biomarker-guided therapeutic decisions are pivotal for precision care. In GCA, the IL6R rs2228145 variant predicts attenuated response to IL-6-receptor inhibition, while CH screening (DNMT3A/TET2 mutations) identifies patients at higher risk of relapse and vascular complications. Molecular signatures reflecting IFN/JAK, IL-17, and GM-CSF pathway activity may further guide tailored treatment. Omics-derived targets such as ULK3 and SLAMF7 in GCA and EGR1 in TAK offer opportunities for drug repurposing and novel interventions. Critical unmet needs include high-quality randomised head-to-head trials comparing biologics and targeted synthetic DMARDs (e.g., TCZ vs TNFi vs JAKi) in TAK, and adaptive, biomarker-stratified trial designs in both GCA and TAK. Standardised, disease-specific endpoints must be defined, considering nuances such as the impact of IL-6-receptor blockade on CRP concentrations, and protocols for GC tapering and immunosuppressive therapy duration require validation. Safety surveillance is especially important in GCA given the older patient population. Looking forward, integrating early, biomarker-driven combination therapies with optimised GC strategies promises to improve outcomes. Validation of genetic (IL6R, IL17A), somatic (CH), cellular (Th1/Th17/CD8), and imaging biomarkers is essential to enable individualised treatment, facilitating precise risk stratification and targeted therapy selection. In summary, while therapeutic advances have transformed LVV management, personalised treatment approaches based on mechanistic insights and biomarker guidance will be key to overcoming current challenges and optimising long-term disease control. Validating genetic, somatic, cellular, and imaging biomarkers will enhance individualised care and improve long-term outcomes in LVV. Funding Open access funding provided by Medical University of Graz. No funding was received. Declarations Conflict of Interest MR: Consultancy: Lilly; Adboard/speaker fees: Alfasigma, Novartis. JT: Consultancy: AbbVie, Janssen, Lilly, Novartis, CSL Behring/Vifor, GSK, AstraZeneca; Speaker Honoraria: AbbVie, Galapagos, Janssen, BMS, Lilly, Vifor, StreamedUp, CSL Behring/Vifor, GSK, AstraZeneca; Research funding: BMS, GSK; Patent application: Pending patent application for the use of secukinumab in GCA. PB: Adboard/speaker fees by Johnsson and Johnsson, AbbVie, Lilly and UCB, Novartis; Project grants: Pfizer. Ethical Approval Not applicable. Consent to Participate Not applicable. Consent for Publication Not applicable. Availability of Data and Materials Not applicable Code Availability Not applicable. Author Contributions MR performed the literature search and drafted the manuscript. JT and PB reviewed the content critically for intellectual input and revised the manuscript. All authors read and approved the final manuscript. References Associated Data Data Availability Statement Not applicable